Pandemic Research: Why Must Trial Results Be Shared?

Why does sharing trial results matter for pandemic care?

Building pandemic preparedness requires a reliable record of what treatments and preventive measures actually achieve. The WHO appeal supplied as the starting point for this story was published on March 20, 2024; it is historical context, rather than a new announcement. The World Health Assembly subsequently adopted the WHO Pandemic Agreement on May 20, 2025. These milestones frame a continuing scientific challenge: turning research into evidence that health services can use. [WHO's original appeal](https://www.who.int/news/item/20-03-2024-call-for-urgent-agreement-on-international-deal-to-prepare-for-and-prevent-future-pandemics), [WHO's adoption announcement](https://www.who.int/news/item/20-05-2025-world-health-assembly-adopts-historic-pandemic-agreement-to-make-the-world-more-equitable-and-safer-from-future-pandemics).

When favorable findings are easier to find than disappointing or inconclusive results, the available literature can exaggerate a treatment's promise. Missing findings can also obscure adverse effects and encourage researchers to repeat questions that earlier studies already addressed. WHO has warned that incomplete disclosure can distort research priorities and treatment decisions. The practical implication is that reporting a well-conducted study showing no clear benefit can be valuable for patient care, even when it produces no breakthrough headline. [WHO's explanation of research transparency](https://www.who.int/news-room/detail/14-04-2015-who-calls-for-increased-transparency-in-medical-research).

What does research show about missing outbreak trial results?

Christopher W. Jones and colleagues examined 333 registered trials associated with the 2009 H1N1 influenza, 2014 Ebola and 2016 Zika outbreaks. Their analysis, published in BMC Medical Research Methodology in 2021, found that 59 trials had no results available in either a registry or a peer-reviewed publication at the final searches in September and October 2020. Only 139 trials met at least one of the reporting benchmarks assessed: registry results within 12 months or journal publication within 24 months of primary completion. [Read the original analysis](https://doi.org/10.1186/s12874-021-01324-8).

These findings describe an older research cohort, not the reporting rate for trials conducted today. The analysis also cannot establish that every missing study had unfavorable findings or quantify resulting patient harm. Its direct contribution is to document gaps between conducting research and making its results accessible. Reporting delays therefore deserve attention alongside the speed of launching studies. [Study methods and limitations](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185489/).

How can researchers make results available quickly and responsibly?

WHO's 2015 disclosure statement set out complementary reporting routes: post key results in a registry within 12 months of study completion, submit the main findings to a journal within 12 months, and make those findings publicly available within 24 months at the latest. WHO explicitly encouraged shorter timelines. These are reporting standards, and the longer publication window does not replace the earlier registry target. They also should not be interpreted as a reason to delay findings needed during an emergency. [WHO's reporting statement](https://www.who.int/news/item/09-04-2015-japan-primary-registries-network).

A 2025 joint statement from research funders went further in encouraging rapid, responsible sharing of interpretable findings during public health emergencies, including negative results. It also supported accessible protocols, statistical analysis plans and appropriately de-identified data. These materials help reviewers understand how outcomes were chosen and analyzed. Publishing aggregate findings does not require exposing identifiable patient records. A practical implication is that research teams should budget for analysis, reporting and secure data access from the outset, so that dissemination remains possible after recruitment ends. [Joint statement on strengthening clinical trials](https://cdn.who.int/media/docs/default-source/research-for-health/joint-statement-on-strengthening-clinical-trials-2025.pdf).